Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Lucas, Guillaume ^a   Du, Jenny ^a   Romeas, Thomas ^a   Mnie Filali, Ouissame ^a,b   Haddjeri, Nasser ^b   Piñeyro, Graciela ^a   Debonnel, Guy ^c  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITÉ LYON 1   (France)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUOXETINE; FLUVOXAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PRUCALOPRIDE; ANILINE DERIVATIVE; ANTIDEPRESSANT AGENT; BENZOFURAN DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG EFFICACY; DRUG POTENTIATION; FORCED SWIMMING TEST; HIPPOCAMPUS; MALE; NERVE CELL; NONHUMAN; POSTSYNAPTIC POTENTIAL; PROTEIN PHOSPHORYLATION; RAT; ACTION POTENTIAL; ANIMAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; PHOSPHORYLATION; PHYSIOLOGY; RAPHE NUCLEUS; SPRAGUE DAWLEY RAT;

RATTUS;

ACTION POTENTIALS; ANILINE COMPOUNDS; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; CA3 REGION, HIPPOCAMPAL; CITALOPRAM; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DRUG SYNERGISM; FLUVOXAMINE; MALE; MOTOR ACTIVITY; NEURONS; PHOSPHORYLATION; PIPERAZINES; PIPERIDINES; PYRIDINES; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 77949523855     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009253     Document Type: Article

References (46)

1. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476.
2. Lengyel K, Pieschl R, Strong T, Molski T, Mattson G, et al. (2008) Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: methodology and biological significance. Neuropharmacology 55: 63-70.
3. Thase ME (2002) What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 63: 95-103.
4. Shelton RC, Papakostas GI (2008) Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 117: 253-259.
5. Trivedi MH (2003) Treatment-resistant depression: new therapies on the horizon. Ann Clin Psychiatry 15: 59-70.
6. Blier P (2001) Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 62(Suppl 4): 7-11.
7. Artigas F, Nutt DJ, Shelton R (2002) Mechanism of action of antidepressants. Psychopharmacol Bull 36(Suppl 2): 123-132.
8. 1A agonists in the treatment of depression? Biol Psychiatry 53: 193-203.
9. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220-226.
10. Blier P, de Montigny C (1999) Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21(Suppl): 91S-98S.
11. Michelsen KA, Schmitz C, Steinbusch HW (2007) The dorsal raphe nucleus - from silver stainings to a role in depression. Brain Res Rev 55: 329-342.
12. 4 receptors exert a frequency-related facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. Eur J Neurosci 16: 817-822.
13. 4 agonists. Biol Psychiatry 15: 918-925.
14. 4) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 55: 712-725.
15. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809.
16. Furukawa TA, Cipriani A, Barbui C, Geddes JR (2007) Long-term treatment of depression with antidepressants: a systematic narrative review. Can J Psychiatry 52: 545-552.
17. Hajos M, Hajos-Korcsok E, Sharp T (1999) Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 126: 1741-1750.
18. Sanchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, et al. (2003) Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167: 353-362.
19. 1A receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. Eur J Pharmacol 382: 133-138.
20. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, et al. (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47: 818-829.
21. Sprouse J, Braselton J, Reynolds L, Clarke T, Rollema H (2001) Activation of postsynaptic 5-HT1A receptors by fluoxetine despite the loss of firing-dependent serotonergic input: electrophysiological and neurochemical studies. Synapse 41: 49-57.
22. 1A receptors induced by venlafaxine. Neuropsychopharmacology 23: 294-306.
23. Lucas G, Rymar VV, Sadikot AF, Debonnel G (2008) Further evidence for an antidepressant potential of the selective sigma1 agonist SA 4503: electrophysiological, morphological and behavioural studies. Int J Neuropsychopharmacol 11: 485-495.
24. 1A receptors. J Neurosci 18: 10150-10156.
25. Besson A, Haddjeri N, Blier P, de Montigny C (2000) Effects of the coadministration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 10: 177-188.
26. Briejer MR, Bosmans JP, Van Daele P, Jurzak M, Heylen L, et al. (2001) The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 423: 71-83.
27. Martín-Ruiz R, Ugedo L (2001) Electrophysiological evidence for postsynaptic 5-HT1A receptor control of dorsal raphe 5-HT neurones. Neuropharmacology 41: 72-78.
28. Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19: 467-489.
29. 4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br J Pharmacol 115: 1387-1392.
30. Chaput Y, de Montigny C, Blier P (1986) Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 333: 342-348.
31. Haddjeri N, Lavoie N, Blier P (2004) Electrophysiological evidence for the tonic activation of 5-HT1A autoreceptors in the rat dorsal raphe nucleus. Neuropsychopharmacology 29: 1800-1806.
32. Nibuya M, Nestler EJ, Duman RS (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16: 2365-2372.
33. Thome J, Sakai N, Shin K-H, Steffen C, Zhang Y-J, et al. (2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20: 4030-4036.
34. Tiraboschi E, Tardito D, Kasahara J, Moraschi S, Pruneri P, et al. (2004) Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology 29: 1831-1840.
35. Duman RS (1998) Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 44: 324-335.
36. Lucas G (2008) Fast-acting antidepressants: are we nearly there? Expert Rev Neurother 8: 1-3.
37. Duman RS (2007) A silver bullet for the treatment of depression? Neuron 55: 679-681.
38. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
39. Artigas F, Perez V, Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 248-251.
40. Artigas F, Adell A, Celada P (2006) Pindolol augmentation of antidepressant response. Curr Drug Targets 7: 139-147.
41. Fujita M, Charney DS, Innis RB (2000) Imaging serotonergic neurotransmission in depression: hippocampal pathophysiology may mirror global brain alterations. Biol Psychiatry 48: 801-812.
42. 11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24: 209-229.
43. Aghajanian GK (1978) Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. In: Youdim MBH, Lovenbery W, Sharman DF, Lagnado JR, eds. Essays in Neurochemistry and Neuropharmacology. New-York: Wiley. pp 1-32.
44. Kandel ER, Spencer WA (1961) Electrophysiology of hippocampal neurons. II. After-potentials and repetitive firing. J Neurophysiol 24: 243-259.
45. Piñeyro G, Azzi M, De Lean A, Schiller P, Bouvier M (2001) Short-term inverse-agonist treatment induces reciprocal changes in delta-opioid agonist and inverse-agonist binding capacity. Mol Pharmacol 60: 816-827.
46. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732